Bristol-Myers Squibb Co Issues FY 2013 Guidance In Line With Analysts' Estimates
Bristol-Myers Squibb Co announced that for fiscal 2013, it expects GAAP EPS in the range of $1.54-$1.64 and non-GAAP EPS in the range of $1.78-$1.88. Fiscal 2013 worldwide sales is expected to be between $16.2 billion and $17.0 billion. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $1.83 and revenue of $16.6 billion for fiscal 2013.
Latest Developments for Bristol-Myers Squibb Co
- Bristol-Myers Squibb Co Receives US FDA sNDA Approval For Use Of SUSTIVA (efavirenz) In HIV-1 Infected Pediatric Patients
- Bristol-Myers Squibb Co Reaffirms FY 2013 EPS Guidance
- Bristol-Myers Squibb Co's and Sanofi SA's Plavix to Be Investigated by U.S. Department of Justice-Reuters
- UK Cost Agency Rejects Drugs From Bristol-Myers Squibb Co, Roche Holding AG And AstraZeneca PLC-Reuters
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters